| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $35.6M | +370.2% |
| R&D Expense | $8.9M | -25.2% |
| SG&A Expense | $35.2M | -40.1% |
| Operating Income | -$12.2M | +81.5% |
| Income Tax | $0 | — |
| Net Income | -$17.9M | +76.6% |
| EPS (Basic) | -$1.68 | -13.5% |
| EPS (Diluted) | -$1.68 | -13.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $30.1M | -34.9% |
| Accounts Receivable | $5.3M | — |
| Inventory | $2.2M | -9.2% |
| Current Assets | $42.5M | -16.9% |
| Total Assets | $47.1M | -12.9% |
| Current Liabilities | $16.4M | -43.3% |
| Long-term Debt | $0 | -100.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$17.6M | +71.1% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $0 | +100.0% |
| Financing Cash Flow | $1.4M | -96.2% |
| Free Cash Flow | -$17.6M | +71.1% |
| Total Liabilities |
| $22.4M |
| -65.0% |
| Stockholders' Equity | $24.7M | +350.9% |